Discover how the Inflation Reduction Act benefits Medicare Part D by reducing prescription costs and improving health outcomes for beneficiaries.

Eli Lilly's weight-loss drug plans face challenges with Medicare's $50 cap on out-of-pocket costs, impacting insurance regulations.

Explore the critique of Trump’s healthcare policies and their impact on insurance costs and access. Understand the implications for families and consumers.

The Supreme Court's rulings and CMS drug price negotiations may impact insurance compliance. Explore regulations affecting the insurance industry today.

Explore AHA's response to the CMS's proposed drug pricing model aiming to lower costs under Medicare Part B while addressing hospital concerns.

Explore the implications of the Trump Administration's MFN pricing and CMS's GLOBE and GUARD models on Medicare and pharmaceutical manufacturers. Act now!

Oregon reinstates annual price increase reports for drug pricing transparency. Learn how this affects insurance compliance, risk management, and industry standards.

Discover how PBMs influence Medicare and Medicaid markets, focusing on drug prices, regulation, and accountability in healthcare practices.

Discover how the new federal reforms on pharmacy benefit managers are reshaping health plans and Medicare Part D with a focus on transparency and compliance.

Explore how the 2026 healthcare cost changes will impact insurance, with strategic insights on Medicare, ACA, and new drug pricing structures.